Breast cancer predictive factor testing: The challenges and importance of standardizing tissue handling

Journal of the National Cancer Institute - Monographs

Volumn , Issue 42, 2011, Pages 43-45

  Hicks, David G ^a   Kushner, LeeAnn ^a   McCarthy, Kristin ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROGESTERONE RECEPTOR; TUMOR MARKER;

ACCURACY; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER TISSUE; HEART MUSCLE ISCHEMIA; ISCHEMIA; MEDICAL SOCIETY; OPERATING ROOM; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELIABILITY; STANDARDIZATION; TISSUE PRESERVATION; UNIVERSITY; VALIDATION STUDY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; FEMALE; HUMAN; LABORATORY DIAGNOSIS; METHODOLOGY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; REPRODUCIBILITY; STANDARD;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; PATHOLOGY, SURGICAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING; TUMOR MARKERS, BIOLOGICAL;

EID: 80053434129     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgr003     Document Type: Article

References (13)

1. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-2502.
2. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004;96(3):218-228.
3. Hicks DG, Kulkarni S. Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. Arch Pathol Lab Med. 2008;132(6):1008-1015.
4. Yaziji H, Taylor CR, Goldstein NS, et al. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol. 2008;16(6):513-520.
5. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784-2795.
6. Goldstein NS, Hewitt SM, Taylor CR, Yaziji H, Hicks DG. Members of Ad-Hoc Committee On Immunohistochemistry Standardization. Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol. 2007;15(2):124-133.
7. Hewitt SM, Lewis FA, Cao Y, et al. Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med. 2008;132(12):1929-1935.
8. Dash A, Maine IP, Varambally S, Shen R, Chinnaiyan AM, Rubin MA. Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. Am J Pathol. 2002;161(5):1743-1748.
9. Miyatake Y, Ikeda H, Michimata R, et al. Differential modulation of gene expression among rat tissues with warm ischemia. Exp Mol Pathol. 2004;77(3):222-230.
10. Nkoy FL, Hammond ME, Rees W, et al. Variable specimen handling affects hormone receptor test results in women with breast cancer: a large multihospital retrospective study. Arch Pathol Lab Med. 2010;134(4):606-612.
11. Khoury T, Sait S, Hwang H, et al. Delay to formalin fixation effect on breast biomarkers. Mod Pathol. 2009;22(11):1457-1467.
12. Sherman ME, Howatt W, Blows FM, Pharoah P, Hewitt SM, Garcia-Closas M. Molecular pathology in epidemiologic studies: a primer on key considerations. Cancer Epidemiol Biomarkers Prev. 2010;19(4):966-972.
13. Kulkarni S, Hicks DG. HER2-positive early breast cancer and trastuzumab: a surgeon's perspective. Ann Surg Oncol. 2008;15(6):1677-1688.